» Articles » PMID: 23642241

Microfluidics and Coagulation Biology

Overview
Publisher Annual Reviews
Date 2013 May 7
PMID 23642241
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

The study of blood ex vivo can occur in closed or open systems, with or without flow. Microfluidic devices, which constrain fluids to a small (typically submillimeter) scale, facilitate analysis of platelet function, coagulation biology, cellular biorheology, adhesion dynamics, and pharmacology and, as a result, can be an invaluable tool for clinical diagnostics. An experimental session can accommodate hundreds to thousands of unique clotting, or thrombotic, events. Using microfluidics, thrombotic events can be studied on defined surfaces of biopolymers, matrix proteins, and tissue factor, under constant flow rate or constant pressure drop conditions. Distinct shear rates can be generated on a device using a single perfusion pump. Microfluidics facilitated both the determination of intraluminal thrombus permeability and the discovery that platelet contractility can be activated by a sudden decrease in flow. Microfluidic devices are ideal for multicolor imaging of platelets, fibrin, and phosphatidylserine and provide a human blood analog to mouse injury models. Overall, microfluidic advances offer many opportunities for research, drug testing under relevant hemodynamic conditions, and clinical diagnostics.

Citing Articles

Microfluidics as a promising technology for personalized medicine.

Oushyani Roudsari Z, Esmaeili Z, Nasirzadeh N, Heidari Keshel S, Sefat F, Bakhtyari H Bioimpacts. 2025; 15:29944.

PMID: 39963565 PMC: 11830131. DOI: 10.34172/bi.29944.


Injury-on-a-chip for modelling microvascular trauma-induced coagulation.

Deal H, Byrnes E, Pandit S, Sheridan A, Brown A, Daniele M Lab Chip. 2025; 25(3):440-453.

PMID: 39763291 PMC: 11704661. DOI: 10.1039/d4lc00471j.


Thrombogenicity of biodegradable metals.

Anderson D, Le H, Vu H, Johnson J, Aslan J, Goldman J Bioact Mater. 2024; 38:411-421.

PMID: 38774458 PMC: 11107095. DOI: 10.1016/j.bioactmat.2024.05.002.


Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies.

Gurkan U, Wood D, Carranza D, Herbertson L, Diamond S, Du E Lab Chip. 2024; 24(7):1867-1874.

PMID: 38487919 PMC: 10964744. DOI: 10.1039/d3lc00796k.


Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow.

Keeling N, Wallisch M, Johnson J, Le H, Vu H, Jordan K J Thromb Haemost. 2024; 22(5):1433-1446.

PMID: 38331196 PMC: 11055672. DOI: 10.1016/j.jtha.2024.01.023.


References
1.
Sakariassen K, Sixma J . Factor VIII-von Willebrand factor requires calcium for facilitation of platelet adherence. Blood. 1984; 63(5):996-103. View

2.
de Groot P, van Mourik J, Sixma J . Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest. 1988; 82(1):65-73. PMC: 303477. DOI: 10.1172/JCI113602. View

3.
Tormoen G, Haley K, Levine R, McCarty O . Do circulating tumor cells play a role in coagulation and thrombosis?. Front Oncol. 2012; 2:115. PMC: 3437466. DOI: 10.3389/fonc.2012.00115. View

4.
Neeves K, Diamond S . A membrane-based microfluidic device for controlling the flux of platelet agonists into flowing blood. Lab Chip. 2008; 8(5):701-9. PMC: 2612095. DOI: 10.1039/b717824g. View

5.
Goel M, Diamond S . Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets. J Biol Chem. 2003; 278(11):9458-63. DOI: 10.1074/jbc.M211956200. View